Conventional first-line treatment continues until disease progression or intolerable toxicities. Today, the majority of patients discontinue due to side effects of chemotherapy. Recent studies have investigated the place of intermittent and continuous treatment regimens in patients with mCRC. Which is the best treatment approach? What impact do they have on potential outcomes? And which patients would best benefit from each approach? The following e-learning course includes expert opinion on the latest answers to these important questions.